June 19, 2017

Gold rush into **Belgian & US** collaboration in immuno-oncology

09:00

Registration

10:00

Introduction

- Welcome address on behalf of the organizers
- Setting the scene on immuno-oncology academic and industrial Belgian Expertise

10:20

The promising future of immune-oncology treatments: US/Belgian showcase

- LifeTech on behalf of Bordet and EORTC to present Clinical Trial in oncology
- Introducing AbbVie's research and development in immune-oncology and their collaboration with the Belgian Argenx

Niels P. Emmerich, Ph.D., Senior Director, Head Search and Evaluation Oncology **AbbVie** Debbie Allen, VP Business Development **Argenx**

"Bringing breakthrough pioneering T cell therapies exploiting NK receptors to patients with life-threatening diseases"



a personal and a state a

18 18 10 **B** (1

Belgian Session

Click

on me

FREE ACCES

JULES BORDET



Celyad Moffitt Cancer Center

"Potent & Scalable active immunotherapies for cancer based on a Plasmacytoid Dendritic Cell line

Eric Halioua, CEO PDC Line Pharma

"Combining the strengths of Pfizer and iTeos to develop novel immunotherapies "

Michel Detheux, CEO **iTeos Therapeutics**

Pfizer Pharmaceuticals

Moderator :



🄰 Celyad



BIOVOX

12:00	13:00
Networking - walking lunch	End

Organizers











With the kind support of





FLANDERS INVESTMENT & TRADE